Clinical Trial

The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer

Name: The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer — clinical trial record (NCT07638878)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery

Trial Details

NCT Number	NCT07638878
Lead Sponsor	Guangzhou Medical University
Conditions	Lung Cancer (Locally Advanced or Metastatic)
Enrollment	30 participants
Start Date	2020-11-06
Primary Completion	2027-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-10